261 zoekresultaten voor “biomarker discovery” in de Publieke website
-
Multi-Biomarker Pharmacokinetic-Pharmacodynamic Relationships of Central Nervous Systems Active Dopaminergic Drugs
Discovery and development of Central Nervous System (CNS) drugs is hampered by high attrition rates.
-
Activity-based protein profiling in drug discovery
In the last decades, activity-based protein profiling (ABPP) has emerged as a powerful chemical tool that may aid the ever-challenging drug discovery process.
-
Microengineered Human Blood Vessels For Next Generation Drug Discovery
Heart failure is a major health care problem with high mortality.
-
Modern Drug Discovery
How are new drugs developed? This question is central to the Minor Modern Drug Discovery (MDD), which covers the entire trajectory from disease to drug molecule and vice versa. The various research groups involved offer a complementary and interdisciplinary perspective by connecting the diverse subjects…
-
Drug Discovery & Safety
In het onderzoeksprogramma Drug Discovery & Safety zijn we geïnteresseerd in de werkzaamheid en veiligheid van nieuwe medicijnen en nieuwe manieren om deze aspecten te bepalen. Daarvoor combineren we geavanceerde imaging en high-throughput screening technieken met computationele aanpakken zoals chem-…
-
Circulating cells as biomarkers in cardiovascular disease : the difference between men and women
Promotor: J. Kuiper
-
Drug Discovery and Safety (MSc)
In deze opleiding ontwikkel je je onderzoek skills en verbreed je je kennis over de meest moderne en geavanceerde technieken die je nodig hebt als onderzoeker op het gebied van target finding en het ontwerp en de synthese van nieuwe geneesmiddelen.
-
Glycoproteomics assays for prostate cancer biomarker discovery
Promotie
-
Immunity in atherosclerosis: novel assays, biomarkers and therapeutic approaches
Atherosclerosis is a progressive disease resulting in the formation of an arterial plaque. Despite lipid lowering, recurrent cardiovascular events remain a risk. While atherosclerosis is primarily lipid-driven, the immune system plays a critical role in the pathophysiology.
-
Novel target engagement biomarkers for better drug candidates
M van der Stelt
-
Inhibitor discovery of phospholipases and N-acyltransferases
In this thesis an activity-based probe was discovered that could visualize the activity of PLAATs. With an optimized gel-based ABPP assay in hand, screening of a compound library led to the discovery of alpha-ketoamides as a hit for PLAAT3.
-
Postdoc AI and physics based drug discovery
Wiskunde en Natuurwetenschappen, Instituut Biologie Leiden (IBL), Leiden Academic Centre for Drug Research (LACDR)
-
Discovery of antibiotics and their targets in multidrug-resistant bacteria
Global healthcare is on the verge of an antibiotic availability crisis as bacteria have evolved resistance to nearly all known antibacterials. Identifying new antibiotics that operate via novel modes-of-action is therefore of high priority.
-
Discovery of Reversible Monoacylglycerol Lipase Inhibitors
Monoacylglycerol lipase (MAGL) is the principal enzyme responsible for hydrolysis of the endocannabinoid 2-arachidonoylglycerol (2-AG). MAGL inhibition provides several potential therapeutic opportunities, including anti-nociceptive, anti-inflammatory and anti-cancer activity.
-
Masterstudent Maddalena Centanni wint Arenberg-Coimbragroep-prijs
Voormalig masterstudent Bio-Farmaceutische Wetenschappen Maddalena Centanni is dit jaar de winnaar van de Arenberg-Coimbragroep-Prijs voor Erasmusstudenten. Centanni bracht voor haar Erasmus-uitwisseling zes maanden door in Uppsala, Zweden. Hier onderzocht ze manieren om de dosering van anti-kankermedicijnen…
-
Glyco(proteo)mic Workflows for Cancer Biomarker Discovery
Promotie
-
Discovery and characterization of new glucosylated metabolites: pathophysiological consequences
Within this thesis the central stage is taken by the discovery and investigation of transglycosylation of sterols. First, investigation focuses on the development of a method to accurately detect and quantify glucosylated metabolites in biological materials.
-
Quantitative pharmacological modelling for optimizing treatment of sepsis
Sepsis is a life-threatening condition caused by a dysregulated host response to infection, it is associated with significant morbidity, mortality, and with a high financial burden on global healthcare systems. Bacterial infections are the primary cause of sepsis, but the growing prevalence of antimicrobial…
-
Discovery of BUB1 kinase inhibitors for the treatment of cancer
The spindle-assembly checkpoint (SAC) is a safety mechanism which secures accurate chromosome segregation during mitosis.
-
Antibiotic Discovery: From mechanistic studies to target ID
The investigations described in this thesis lay out strategies aimed at advancing antibiotic research and development. The examples presented revolve around two main approaches: understanding drug-target interactions and target identification.
-
Biomarkers for the response to immunotherapy in patients with non- small cell lung cancer
Promotie
-
Discovery of FLT3 inhibitors for the treatment of acute myeloid leukemia
The disease acute myeloid leukemia (AML) is characterized by fast progression and low survival rates.
-
Discovery of novel inhibitors to investigate diacylglycerol lipases and α/β hydrolase domain 16A
Promotor: H.S. Overkleeft, Co-promotor: M. van der Stelt
-
Proteins in harmony: Tuning selectivity in early drug discovery
This thesis describes the importance of being able to control the selectivity of potential drug candidates.
-
Harnessing zebrafish xenograft models for ocular melanoma treatment discovery
The aim of this thesis was to develop novel treatment strategies for different types of eye melanoma utilizing zebrafish models. We first establish orthotopic and ectopic xenograft models for uveal and conjunctival melanoma by engraftment of the immortalized cells derived from these tumors into zebrafish…
-
Singing Basics: A Vocal Discovery in 6 weeks
Kunst en vrije tijd, Kunst en vrije tijd
-
Causal Discovery from High-Dimensional Data in the Large-Sample Limit
Developing robust algorithms and theory for establishing cause-effect relationships from observational data that scale up to large data sets
-
Discovery of novel Antibiotics from Actinomycetes by Integrated Metabolomics & Genomics Approaches
Promotor: G.P. van Wezel, Co-promotor: Y.H. Choi
-
Genomics driven metabolomics novel strategies for the discovery and identification of secondary metabolites
Promotor: T. Hankemeier, Co-promotor: R.J. Vreeken
-
data into knowledge for intelligent decision-making in early drug discovery
Promotor: A.P.IJzerman Co-promotor: A. Bender
-
Knowledge discovery from patient forums: gaining novel medical insights from patient experiences
Patients share valuable advice and experiences with their peers in online patient discussion groups.
-
Developing metabolomics for a systems biology approach to understand Parkinson's disease
Neurodegenerative diseases, including Parkinson’s disease (PD), are increasing in prevalence due to the aging population. Despite extensive study, these diseases are still not fully understood and the lack of personalised treatment options that can target the cause of the diseases, rather than the symptoms,…
-
Image-based phenotypic screening for breast cancer metastasis drug target discovery
The main aim of this thesis was to unravel the signaling and regulatory networks that drive tumor cell migration during breast cancer metastasis.
-
Discovery and exploitation of the transcriptional regulatory system of pectinases in Aspergillus niger
Pectin is a plant cell wall polysaccharide made of mainly D-galacturonic acid (GA) subunits. The potency of the filamentous fungus Aspergillus niger to naturally secrete high amounts of pectinases to degrade pectin has been utilized for the industrial production of pectinases.
-
Discovery and development of inhibitors selective for human constitutive proteasome and immunoproteasome active sites
This thesis describes the design and development of subunit‐selective inhibitors of particular catalytically active subunits of human constitutive proteasomes and immunoproteasomes.
-
Dynamics and regulation of the oxidative stress response upon chemical exposure
The focus of the described research in this thesis is on the oxidative stress response (Nrf2 pathway). The aim of the research presented in this thesis is to obtain more information concerning microRNAs which are involved in the Nrf2 pathway, to determine and evaluate the application of microRNAs for…
-
Oratie: Toekomstmedicijn
Acht op de tien experimentele geneesmiddelen overleven de testfase op patiënten niet. Piet Hein van der Graaf, hoogleraar Systeemfarmacologie, wil die verspilling van tijd en geld voorkomen met nieuwe meet- en rekenmethoden.
-
Cancer Drug Discovery Initiative maakt nieuwe therapieën tegen kanker mogelijk
Het Antoni van Leeuwenhoek/Nederlands Kanker Instituut, het Leids Instituut voor de Chemie en het Pivot Park Screening Centre gaan kennis en infrastructuur delen in het Cancer Drug Discovery Initiative. Vrijdag 11 oktober tekenden ze een letter of intent.
-
Quantitative pharmacology of antimicrobials
Antimicrobial drugs constitute a fundamental part of modern medicine. The global rise in antimicrobial resistance poses a major threat to global health.
-
Twee Leidse finalisten Academische Jaarprijs op Discovery Festival
Universiteit Leiden is op 28 september met twee projecten aanwezig bij het Discovery Festival, een nachtfestival dat draait om de kick die je krijgt als je nieuwe dingen ontdekt. Antibiotica Gezocht! laat de festivalgangers meewerken in het tijdelijke laboratorium en iSPEX: ‘Meet fijnstof met je smartphone’…
-
Nieuwe geneesmiddelen: eerst rekenen, dan pas testen op patiënten
Acht op de tien experimentele geneesmiddelen overleven de testfase op patiënten niet. Piet Hein van der Graaf, hoogleraar Systeemfarmacologie, wil die verspilling van tijd en geld voorkomen met nieuwe meet- en rekenmethoden. Oratie 27 mei.
-
Erik Danen benoemd tot hoogleraar Cancer drug target discovery
Met ingang van 1 april 2018 is Erik Danen benoemd tot hoogleraar Cancer drug target discovery bij het Leiden Academic Centre for Drug Research (LACDR). Zijn vakgebied is celbiologie van kanker, waarin hij zich richt op de achterliggende mechanismen bij uitzaaiingen en resistentie voor behandelingen.
-
A pharmacognostic study of Vernonia guineensis Benth. (Asteraceae): bioactivity, safety, and phytochemical analysis
Promotor: Prof.dr. R. Verpoorte, Co-Promotor: Dr. Young Hae Choi
-
NMR structural studies of protein-small molecule interactions
Promotor: Prof.dr. M. Ubbink, Co-promotor: G. Siegal
-
Freek Vonk krijgt eigen show op Discovery Channel
In het programma Time Warp brengt bioloog Freek Vonk de gevaarlijkste gifslangen ter wereld voor de camera. Zijn doel is niet het tonen alleen, maar vooral het melken van het slangengif ten behoeve van zijn promotieonderzoek. Vrijdag vertelde hij over zijn fascinatie voor slangen in 'De Wereld Draait…
-
Quantitative systems pharmacology modeling of biotherapeutics in oncology
In this thesis, mathematical modeling and simulation was applied as a tool to inform quantitative decision making in oncology drug discovery and development.
-
Astronoom Joe Callingham getuigt tegen killer-sterren in nieuwe show op Discovery
Op vrijdagavond 17 september is de Leidse astronoom Joe Callingham te zien in een nieuwe serie op Discovery. ‘Killers of The Cosmos’ gaat over krachten in het heelal die ons bestaan kunnen bedreigen. Asteroïden, kosmisch puin, elektromagnetische wapens… De show behandelt elke bedreiging als potentiële…
-
Mechanistic modelling of drug target binding kinetics as determinant of the time course of drug action in vivo
Drug-target binding kinetics determine the time course of the central event in pharmacotherapy: Drug-target interaction.
-
Towards improved drug action : target binding kinetics and functional efficacy at the mGlu2 receptor
During the course of drug discovery translational steps are made.
-
Sensing Transport
Solute carrier (SLC) transporters are a large and diverse class of relatively understudied transmembrane proteins.